Cargando…
Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma
Haematopoiesis is a tightly orchestrated process where a pool of hematopoietic stem and progenitor cells (HSPCs) with high self-renewal potential can give rise to both lymphoid and myeloid lineages. The HSPCs pool is reduced with ageing resulting in few HSPC clones maintaining haematopoiesis thereby...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406467/ https://www.ncbi.nlm.nih.gov/pubmed/30704144 http://dx.doi.org/10.3390/cells8020103 |
_version_ | 1783401309323395072 |
---|---|
author | Djavaheri-Mergny, Mojgan Giuriato, Sylvie Tschan, Mario P. Humbert, Magali |
author_facet | Djavaheri-Mergny, Mojgan Giuriato, Sylvie Tschan, Mario P. Humbert, Magali |
author_sort | Djavaheri-Mergny, Mojgan |
collection | PubMed |
description | Haematopoiesis is a tightly orchestrated process where a pool of hematopoietic stem and progenitor cells (HSPCs) with high self-renewal potential can give rise to both lymphoid and myeloid lineages. The HSPCs pool is reduced with ageing resulting in few HSPC clones maintaining haematopoiesis thereby reducing blood cell diversity, a phenomenon called clonal haematopoiesis. Clonal expansion of HSPCs carrying specific genetic mutations leads to increased risk for haematological malignancies. Therefore, it comes as no surprise that hematopoietic tumours develop in higher frequency in elderly people. Unfortunately, elderly patients with leukaemia or lymphoma still have an unsatisfactory prognosis compared to younger ones highlighting the need to develop more efficient therapies for this group of patients. Growing evidence indicates that macroautophagy (hereafter referred to as autophagy) is essential for health and longevity. This review is focusing on the role of autophagy in normal haematopoiesis as well as in leukaemia and lymphoma development. Attenuated autophagy may support early hematopoietic neoplasia whereas activation of autophagy in later stages of tumour development and in response to a variety of therapies rather triggers a pro-tumoral response. Novel insights into the role of autophagy in haematopoiesis will be discussed in light of designing new autophagy modulating therapies in hematopoietic cancers. |
format | Online Article Text |
id | pubmed-6406467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64064672019-03-19 Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma Djavaheri-Mergny, Mojgan Giuriato, Sylvie Tschan, Mario P. Humbert, Magali Cells Review Haematopoiesis is a tightly orchestrated process where a pool of hematopoietic stem and progenitor cells (HSPCs) with high self-renewal potential can give rise to both lymphoid and myeloid lineages. The HSPCs pool is reduced with ageing resulting in few HSPC clones maintaining haematopoiesis thereby reducing blood cell diversity, a phenomenon called clonal haematopoiesis. Clonal expansion of HSPCs carrying specific genetic mutations leads to increased risk for haematological malignancies. Therefore, it comes as no surprise that hematopoietic tumours develop in higher frequency in elderly people. Unfortunately, elderly patients with leukaemia or lymphoma still have an unsatisfactory prognosis compared to younger ones highlighting the need to develop more efficient therapies for this group of patients. Growing evidence indicates that macroautophagy (hereafter referred to as autophagy) is essential for health and longevity. This review is focusing on the role of autophagy in normal haematopoiesis as well as in leukaemia and lymphoma development. Attenuated autophagy may support early hematopoietic neoplasia whereas activation of autophagy in later stages of tumour development and in response to a variety of therapies rather triggers a pro-tumoral response. Novel insights into the role of autophagy in haematopoiesis will be discussed in light of designing new autophagy modulating therapies in hematopoietic cancers. MDPI 2019-01-30 /pmc/articles/PMC6406467/ /pubmed/30704144 http://dx.doi.org/10.3390/cells8020103 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Djavaheri-Mergny, Mojgan Giuriato, Sylvie Tschan, Mario P. Humbert, Magali Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma |
title | Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma |
title_full | Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma |
title_fullStr | Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma |
title_full_unstemmed | Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma |
title_short | Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma |
title_sort | therapeutic modulation of autophagy in leukaemia and lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406467/ https://www.ncbi.nlm.nih.gov/pubmed/30704144 http://dx.doi.org/10.3390/cells8020103 |
work_keys_str_mv | AT djavaherimergnymojgan therapeuticmodulationofautophagyinleukaemiaandlymphoma AT giuriatosylvie therapeuticmodulationofautophagyinleukaemiaandlymphoma AT tschanmariop therapeuticmodulationofautophagyinleukaemiaandlymphoma AT humbertmagali therapeuticmodulationofautophagyinleukaemiaandlymphoma |